Tumor Necrosis Factor news

All news on Tumor Necrosis Factor (also known as TNF and Cachectin): plants, production capacities, investments and involved companies in Europe.

6 October 2025
Merck Launches Phase 2b Trials for Tulisokibart in Three Inflammatory Diseases
Merck starts Phase 2b trials for tulisokibart in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis, targeting over 640 patients globally.

Who will be producing Tumor Necrosis Factor in the future?

Find out with chemXplore Analytics